Skip to content
5 min read The Long View Deals and Capital Markets

The Long View: Who Will Finance Discovery When Everyone Can Buy Innovation?

The global market for acquiring pharmaceutical innovation has changed faster than our understanding of its consequences for financing discovery.

A lighthouse with an orange-red tower on a dark, grassy shoreline at night, its beams of light fanning out into a deep blue, cloudy sky and mirrored in still water below.
Sometimes a lighthouse does more than a fleet of expensive ships. Photo by Evgeni Tcherkasski on Unsplash
The holiday season is almost upon us, and we think our regular readers deserve a treat for all the support and feedback we've received over the last few months. It's The Long View and it's time for a deeper look at what is driving the industry and who is at the wheel.

This edition has been authored by physician-scientist and global biotechnology leader Jeremy Levin, who is also a Scrip Lifetime Achievement Award winner.

Pharmaceutical companies have always looked beyond their own labs for new medicines. Acquisitions and partnerships have strengthened pipelines, created value and brought important treatments to patients. I have spent much of my career leading such strategic decisions. At Bristol-Myers Squibb, the ‘String of Pearls’ strategy emerged from an urgent need to reconstruct a company whose pipeline could no longer sustain its future.

We needed a new scientific direction, which meant investing in biologics, withdrawing from less productive areas, and using external innovation to help transform the business. These were deliberate strategic choices, not simply transactions to add products. Yet the experience also taught me that rebuilding a pipeline and establishing the ability to renew it repeatedly are not necessarily the same achievement. 
 
Today, the expanding international supply of promising molecules presents pharmaceutical companies with opportunities that were far less accessible a generation ago. Faced with patent expirations and the need to replenish revenues, they can acquire assets that have already passed important development milestones. Such transactions may offer greater visibility into clinical prospects, remaining development costs, and commercial potential than investments in unproven discovery programs. They can be entirely rational uses of shareholders' capital.